CIMB MDPI’s Post

‼️🧪 This review focuses on the current data on numerous in vivo and in vitro models of liver fibrosis and on various #pharmacotherapeutic targets in the treatment of #liver #fibrosis. 📣 https://lnkd.in/e2Me4HpG

Developing strategies for tissue-specific delivery of extracellular vesicles: in this review article, Junyao Deng, Qishan Li and Fei Wang at Southern Medical University  provided an in-depth overview of recent advancements in EV delivery methods tailored for brain, heart, lung, skin, eye, and gastrointestinal tract-specific applications https://lnkd.in/ea8z59Qr The authors emphasised that innovative EV administration strategies hold great promise for advancing clinical trials and enhancing the practical application of EV-based therapeutics in the future. #extracellularvesicles #exosomes #drugdelivery #translationalmedicine #Vesiculab

Generate human bone marrow organoids from hiPSCs to mimic native hematopoietic tissues. This scalable, in vitro model supports study of healthy and diseased hematopoiesis, aiding research into blood disorders. #pharma #healthcare #human #bones #InformaConnectAcademy

Subcapsular Splenic Hematoma: CT findings https://lnkd.in/eE_PhQ_4

Antidepressant shows promise for treating brain tumours Researchers at ETH Zurich have used a drug screening platform they developed to show that an antidepressant, currently on the market, kills tumour cells in the dreaded glioblastoma – at least in the cell-culture dish. Find out more via ETH Zürich https://lnkd.in/gVNwkXc5 #BrainTumourResearch #Glioblastoma #Antidepressants #CancerTreatment #OncologyResearch #ETHZurich #MedicalResearch #PharmaceuticalScience #TumourCells #InnovativeMedicine

Read our new article in Drug Discovery World! It's estimated that up to half of all #type2diabetes patients will develop some form of diabetic retinopathy within 20 years. Despite this, current treatment strategies are both invasive and limited, imposing a considerable burden on patients and greatly affecting their quality of life. Dr Catherine Beech MB,ChB,OBE and Dr Pete Adamson (Breye Therapeutics ApS) discuss the challenges presented by current treatments for diabetic #eyedisease, and outline innovative research and studies that are paving the way for a new-generation of therapies. Find the latest print issue: https://rb.gy/mv3c5o

💊 Are you curious about the latest FDA-approved #mabdrugs for #Alzheimers? MAB drugs prevent the buildup of amyloid plaques in the #brain. As of mid-2024, both #Leqembi (lecanemab) and #Kisunla (donanemab) have been approved. 🔗 Learn the ins and outs about Alzheimer’s MAB drugs in our latest interactive guide: https://buff.ly/3SRwygP

Congratulations to ProThera Biologics on their NINDS Phase IIb #SBIR award for a project titled "Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury". Cerebral #hypoxia-#ischemia (HI) and associated #inflammation is a profound neurological problem in #neonatal infants. Inter-alpha Inhibitor Proteins (#IAIPs) are naturally derived #glycoproteins that have been demonstrated to play an important role in modulating host inflammatory responses. The goal of this project is to advance IAIPs as an alternative or adjunctive to #hypothermia to prevent and/or attenuate HI-related brain damage in neonates.

Exciting news from, member company, Entrada Therapeutics! We're thrilled to hear about their positive preliminary data from the company’s Phase 1 clinical trial of ENTR-601-44. This breakthrough brings us one step closer to transforming the treatment landscape for Duchenne muscular dystrophy. #Biotech #Duchenne #ClinicalTrials #Infrastructure #Investments #Technology #ClinicalTrials #LifeScience #Pharma #Pharmaceutical #DrugDevelopment #DrugManufacturing #ClinicalData #BusinessDevelopment #Biopharma #DrugDiscovery